AgingResearch.NewsJoin free

CuraSen Therapeutics

CompanyUnited States

CuraSen Therapeutics develops one asset, in phase 2 (CST-3056 in neurogenic orthostatic hypotension). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • CST-3056

    Centrally/peripherally acting adrenergic modulator to elevate blood pressure

    Phase 2, Small molecule, neurogenic orthostatic hypotension

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1

Intelligence